Who We Are

Qualisure Diagnostics Inc. develops molecular tests that enhance cancer care by identifying features that help oncologists personalize treatment.

Understanding which cancers are indolent or aggressive, and which ones are more likely to respond to certain treatments can guide treatment strategy.

Through innovation and collaboration, we help clinicians decide on the right treatment to provide personalized cancer care to every patient.

Introducing Thyroid GuidePx®

Helping guide your papillary thyroid cancer treatment journey!

Latest News

Prognostication with Thyroid GuidePx in the context of tall cell variants

The tall cell variant of papillary thyroid cancer generally has a worse prognosis compared with the classical variant. Thyroid GuidePx is a genomic classifier capable of classifying papillary thyroid cancer into 3 molecular subtypes using fine-needle aspirate. Type 1 and 2 have low recurrence rates, particularly in early tumors (1–4 cm and N0). Type 3 is characterized by aggressive biology and high recurrence rates regardless of size and lymph node status. The study examines the interaction of tall cell variant histology with Thyroid GuidePx risk stratification.

Read More »